The Burden of Surgery for Tenosynovial Giant Cell Tumor: A Targeted Review

A Mixed-Methods Analysis to Define Minimum Clinically Importance Differences (MCIDs) in Range of Motion, Physical Function, and Worst Stiffness in Patients with Tenosynovial Giant Cell Tumor (TGCT)

Vimseltinib versus a placebo in patients with tenosynovial giant cell tumor: a plain language summary of the MOTION phase 3 trial

CSF1R Inhibition in Patients with Advanced Solid Tumors or Tenosynovial Giant Cell Tumor: A Phase I Study of Vimseltinib

Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Updated efficacy and safety of vimseltinib in patients (pts) with tenosynovial giant cell tumor (TGCT): One-year follow-up from the MOTION phase III trial

Safety, efficacy, and patient-reported outcomes with vimseltinib in patients with tenosynovial giant cell tumor who received prior anti–colony-stimulating factor 1 therapy: ongoing phase 2 study

Safety and efficacy with vimseltinib in patients with tenosynovial giant cell tumor who received no prior anti–colony-stimulating factor 1 therapy: ongoing phase 2 study

Efficacy, safety, and patient-reported outcomes of vimseltinib in patients with tenosynovial giant cell tumor: Results from the phase 3 MOTION trial

Safety, Efficacy, and Patient-Reported Outcomes with Vimseltinib in Patients with Tenosynovial Giant Cell Tumor Who Received No Prior Anti-Colony-Stimulating Factor 1 Therapy: Ongoing Phase 2 Update.